India Vaccine Market Size & Outlook, 2023-2030

The vaccine market in India is expected to reach a projected revenue of US$ 5,363.6 million by 2030. A compound annual growth rate of 3.3% is expected of India vaccine market from 2024 to 2030.
Revenue, 2023 (US$M)
$4,259.5
Forecast, 2030 (US$M)
$5,363.6
CAGR, 2024 - 2030
3.3%
Report Coverage
India

India vaccine market highlights

  • The India vaccine market generated a revenue of USD 4,259.5 million in 2023 and is expected to reach USD 5,363.6 million by 2030.
  • The India market is expected to grow at a CAGR of 3.3% from 2024 to 2030.
  • In terms of segment, subunit vaccines was the largest revenue generating type in 2023.
  • Subunit Vaccines is the most lucrative type segment registering the fastest growth during the forecast period.


Vaccine market data book summary

Market revenue in 2023USD 4,259.5 million
Market revenue in 2030USD 5,363.6 million
Growth rate3.3% (CAGR from 2023 to 2030)
Largest segmentSubunit vaccines
Fastest growing segmentSubunit Vaccines
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSubunit Vaccines, Inactivated, Live Attenuated, MRNA vaccines, Viral vector vaccines
Key market players worldwideSerum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc


Other key industry trends

  • In terms of revenue, India accounted for 5.6% of the global vaccine market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China vaccine market is projected to lead the regional market in terms of revenue in 2030.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 5,363.6 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Vaccine Market Companies

Name Profile # Employees HQ Website

India vaccine market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine market will help companies and investors design strategic landscapes.


Subunit vaccines was the largest segment with a revenue share of 34.12% in 2023. Horizon Databook has segmented the India vaccine market based on subunit vaccines, inactivated, live attenuated, mrna vaccines, viral vector vaccines covering the revenue growth of each sub-segment from 2018 to 2030.


India has a flourishing pharmaceutical sector owing to the emergence of generic manufacturers and the presence of leading pharmaceutical players. The growth of India influenza vaccines market is driven by increasing prevalence of influenza in the country, coupled with several awareness campaigns arranged by local governments.

In addition, rising government efforts to bring next-generation influenza vaccines into the country is another factor propelling the country’s market. For instance, in August 2018, India and the EU announced a collaboration to develop a next-generation flu vaccine for people in India.

Furthermore, in August 2022, Novavax announced a collaboration with the SII to investigate and develop vaccines against malaria, flu, and RSV in babies. Moreover, Cervavac, India's inaugural indigenous vaccine against cervical cancer, created and produced by the SII in Pune, is now accessible in the private market.

Reasons to subscribe to India vaccine market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of India vaccine market databook

  • Our clientele includes a mix of vaccine market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the India vaccine market , including forecasts for subscribers. This country databook contains high-level insights into India vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

India vaccine market size, by type, 2018-2030 (US$M)

India Vaccine Market Outlook Share, 2023 & 2030 (US$M)

India vaccine market size, by type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more